In a new perspective piece in the journal Neuron, MBI Director Todd Golde, M.D., Ph.D., highlights both the promise and the challenges of a new method being studied as a possible path to treat Alzheimer’s disease and other neurodegenerative disorders.
The prospective method would harness “immunoproteostasis”, or the interplay between the immune system and malformed proteins, which are presumptive “triggers” of such diseases.
“Although there are concerns that manipulation of the immune system may cause more harm than good, there is considerable interest in developing immune modulatory therapies for neurodegenerative disorders,” Golde writes.
Click here to read the paper in Neuron.